GlassScriptPhysician profile
Andrew J King
NPI 1487615886
$2,731.23
in general payments reported to CMS, 2019-2025
13 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $12.48 · 2022: $201 · 2023: $2,022 · 2024: $82.19 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,000 · Food and Beverage: $201 · Education: $59.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,000.00 |
| Food and Beverage | $200.82 |
| Education | $59.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Quanta Dialysis Technologies INC | $2,017.32 | 2022-2023 | |
| Baxter Healthcare | $427.96 | 2019-2024 | Renal - Chronic, Renal - Pd |
| Vantive US Healthcare LLC | $69.42 | 2025 | Renal - Pd |
| Travere Therapeutics, INC. | $45.64 | 2023-2025 | Filspari |
| Pfizer INC. | $42.64 | 2022-2024 | |
| Boston Scientific Corporation | $32.01 | 2022 | |
| Medtronic, INC. | $23.34 | 2025 | Symplicity G3 |
| Astrazeneca Pharmaceuticals LP | $22.10 | 2025 | |
| Cormedix INC. | $18.09 | 2025 | Defencath |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $12.48 | 2020 | |
| Outset Medical INC | $6.63 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.